Completed Cancer NIHR-supported project Lungs & Breathing
A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent, and Pediatric Participants with PMM2-CDG
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Stephanie Grünewald (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
Phase 2, randomised, open-label, 24-week study to assess the pharmacodynamics, safety, tolerability and pharmacokinetics of multiple doses of GLM101 administered intravenously to adult, adolescent and paediatric participants with PMM2-CDG
A Phase 1/2 Open-Label, Multicenter Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subjects Aged 4 to 24 months with Type 1 (Early Onset Infantile) and Aged 6 to 36 Months with Type 2a (Late Onset Infantile) GM1 Gangliosidosis (Imagine-1 Study).
A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of APL-2 in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN
Global, Phase 1, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know